Last reviewed · How we verify
WXFL10030390
WXFL10030390 is a Small molecule drug developed by Shanghai Jiatan Pharmatech Co., Ltd. It is currently in Phase 1 development. Also known as: WX390.
WXFL10030390 is an intervention being studied in a clinical trial for its safety and efficacy in combination with Toripalimab in patients with advanced solid tumors, including gastric type adenocarcinoma with STK11 mutation and PIK3CA mutation-related tumors. The trial, NCT06117566, is being conducted by Shanghai Jiatan Pharmatech Co., Ltd.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | WXFL10030390 |
|---|---|
| Also known as | WX390 |
| Sponsor | Shanghai Jiatan Pharmatech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment (PHASE3)
- A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations (PHASE2)
- A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of WX390 in Patients With Advanced Solid Tumors (PHASE2)
- A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations (PHASE1, PHASE2)
- A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WXFL10030390 CI brief — competitive landscape report
- WXFL10030390 updates RSS · CI watch RSS
- Shanghai Jiatan Pharmatech Co., Ltd portfolio CI
Frequently asked questions about WXFL10030390
What is WXFL10030390?
Who makes WXFL10030390?
Is WXFL10030390 also known as anything else?
What development phase is WXFL10030390 in?
Related
- Manufacturer: Shanghai Jiatan Pharmatech Co., Ltd — full pipeline
- Also known as: WX390
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing